TGA issues fine of $119,880 for alleged unlawful advertising of complementary medicines
Global Therapeutics has paid penalties of $119,880 after being issued nine infringement notices issued by the TGA.
These infringement notices related to the advertising of five listed complementary medicines sponsored by Global Therapeutics.
The Global Therapeutics’ website allegedly contained unapproved references to “serious” conditions such as upper respiratory tract infections, bronchitis, influenza, and viral and bacterial infections, said the TGA.
According to the Therapeutic Goods Advertising Code, conditions are “serious” when they require diagnosis, treatment or supervision by a suitably qualified health professional.
Use of this representation in advertising is restricted by the Code and not permitted for listed medicines.
Global Therapeutics allegedly breached one of these conditions by advertising their medicines for indications that were not accepted in the Australian Register of Therapeutic Goods, said the TGA in a statement.
“Listed medicines are permitted to be supplied and advertised without full pre-market evaluation by the TGA as long as certain fundamental conditions are met to ensure the medicines are low-risk and suitable for self-selection by consumers,” it said.
“The onus is on sponsors to ensure compliance with these ‘conditions of listing’ and all other relevant requirements under the Therapeutic Goods Act 1989.
“Contravening a condition of listing is behaviour that undermines the integrity of the trust-based listed medicines framework.”